Faron Pharmaceuticals Oy (DI) (FARN)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

206.00p
   
  • Change Today:
    -4.00p
  • 52 Week High: 265.00
  • 52 Week Low: 92.50
  • Currency: UK Pounds
  • Shares Issued: 111.60m
  • Volume: 13,437
  • Market Cap: £229.90m

Latest ShareCast News

Faron identifies final patient in BEXMAB phase two study

By Josh White

Date: Friday 31 Jan 2025

(Sharecast News) - Faron Pharmaceuticals announced on Friday that it has identified the final patient for its BEXMAB phase two dose optimisation study in refractory or relapsed myelodysplastic syndrome (r/r MDS) and its phase one and two study in frontline high-risk (HR) MDS.

Faron Pharmaceuticals reports regulatory progress in the UK

By Josh White

Date: Monday 02 Dec 2024

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced significant regulatory progress in the UK for its lead asset bexmarilimab on Monday.

Faron announces promising MDS trial results

By Josh White

Date: Wednesday 27 Nov 2024

(Sharecast News) - Faron Pharmaceuticals announced promising interim phase two results from its 'BEXMAB' trial on Wednesday, targeting relapsed or refractory myelodysplastic syndrome (r/r MDS) patients.

Faron Pharmaceuticals files new patent for Cleve... 11-Nov-2024 ShareCast
Faron Pharmaceuticals candidate gets FDA fast tr... 27-Aug-2024 ShareCast
Faron gets positive FDA feedback on bexmarilimab... 11-Jul-2024 ShareCast
Faron Pharmaceuticals extends funding agreement ... 30-Apr-2024 ShareCast
Faron Pharmaceuticals CFO stands down 15-Apr-2024 ShareCast
Faron Pharmaceuticals taps Juho Jalkanen for CEO 08-Apr-2024 ShareCast
Faron shares jump on encouraging trial data 18-Mar-2024 ShareCast
Faron Pharmaceuticals reports year of clinical p... 13-Mar-2024 ShareCast
Faron Pharmaceuticals shores up cash with EUR 3.... 04-Mar-2024 ShareCast
Faron launches second phase of leukaemia treatme... 09-Jan-2024 ShareCast
Faron unveils promising antibody study results 11-Dec-2023 ShareCast
Faron publishes cancer immunotherapy study findi... 07-Dec-2023 ShareCast
Faron reveals details of next stage of bexmarili... 06-Nov-2023 ShareCast
Faron Pharmaceuticals upbeat on latest data in b... 11-Oct-2023 ShareCast
Faron Pharmaceuticals names interim chief medica... 21-Sep-2023 ShareCast
Faron Pharmaceuticals names James O'Brien as CFO 29-Mar-2023 ShareCast
Faron Pharmaceuticals gets positive feedback fro... 22-Mar-2023 ShareCast
 

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

FARN Market Data

Currency UK Pounds
Share Price 206.00p
Change Today -4.00p
% Change -1.90 %
52 Week High 265.00
52 Week Low 92.50
Volume 13,437
Shares Issued 111.60m
Market Cap £229.90m

FARN Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
Market averageMarket averageMarket averageMarket averageMarket average
53.19% below the sector average53.19% below the sector average53.19% below the sector average53.19% below the sector average53.19% below the sector average
Price Trend
Market averageMarket averageMarket averageMarket averageMarket average
34.69% above the sector average34.69% above the sector average34.69% above the sector average34.69% above the sector average34.69% above the sector average
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 0
Buy 2
Neutral 0
Sell 0
Strong Sell 1
Total 3
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

FARN Dividends

No dividends found

Trades for 28-Mar-2025

Time Volume / Share Price
16:15 250 @ 202.75p
16:12 1,100 @ 208.00p
15:47 1,200 @ 202.75p
15:21 1,410 @ 204.00p
15:15 2,188 @ 206.00p

FARN Key Personnel

CFO Yrjö E K Wichmann
CEO Juho Jalkanen
Chair Tuomo Pätsi

Top of Page